[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351998-105":59,"doc-detail-351998-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","identification-and-validation-of-cntnap2pax1-hypermethylation-as-an-epigenetic-biomarker-panel-for-detection-of-cervical-cancer-and-precancerous-lesions-in-hrhpvpositive-women","Identification and validation of CNTNAP2/PAX1 hypermethylation as an epigenetic biomarker panel for detection of cervical cancer and precancerous lesions in hrHPVpositive women","","Cervical cancer remains a major global health burden, and effective triage is urgently needed for high-risk human papillomavirus (hrHPV)–positive women in screening programs. This study identifies and validates DNA methylation markers to detect cervical precancerous lesions. Reduced representation bisulfite sequencing screened discovery candidates, and quantitative methylation-specific PCR evaluated selected markers in an independent cohort of 347 hrHPV-positive women, assessing diagnostic performance via ROC, sensitivity, specificity, and AUC.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/identification-and-validation-of-cntnap2pax1-hypermethylation-as-an-epigenetic-biomarker-panel-for-detection-of-cervical-cancer-and-precancerous-lesions-in-hrhpvpositive-women/351998/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/identification-and-validation-of-cntnap2pax1-hypermethylation-as-an-epigenetic-biomarker-panel-for-detection-of-cervical-cancer-and-precancerous-lesions-in-hrhpvpositive-women/351998.png","ImageObject",300,407,{"name":92,"@type":93},"Guten tag","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of the study?","Question",{"text":112,"@type":113},"To identify and validate DNA methylation markers, specifically CNTNAP2 and PAX1, for detecting cervical precancerous lesions in hrHPV-positive women.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the methylation markers discovered and tested?",{"text":117,"@type":113},"Reduced representation bisulfite sequencing was used on a discovery cohort to screen candidate genes, and quantitative methylation-specific PCR evaluated performance in an independent training/validation cohort.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the CNTNAP2/PAX1 panel perform in detecting CIN2+ and CIN3+?",{"text":121,"@type":113},"In the independent validation set, the combined panel achieved AUC values of 0.904 for CIN2+ and 0.932 for CIN3+, with high specificity for both endpoints and sensitivity reported for each disease level.",{"name":123,"@type":110,"acceptedAnswer":124},"How did the panel compare with existing triage methods?",{"text":125,"@type":113},"The CNTNAP2/PAX1 panel outperformed HPV16/18 genotyping and showed better overall diagnostic accuracy than cytology, which had higher sensitivity but substantially lower specificity and possible underestimation due to verification bias.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},351998,1790449693,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":41,"preview_page_count":19,"preview_urls":149},687212321768,"https://ap-avatar.wpscdn.com/avatar/a0010bdbe886d2fe77?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789897067658708522","He etal. BMC Cancer (2026) 26:847 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16208-7](https://doi.org/10.1186/s12885-026-16208-7)  \nRESEARCH Open Access  \nIdentification and validation of CNTNAP2/ PAX1 hypermethylation as an epigenetic biomarker panel for detection of cervical cancer and precancerous lesions in hrHPVpositive women  \nYuying He1,2, Haiyan Yang1,3, Chuang Zhang3,4, Ruiwei Jiang3, Kai Kang2, Yuxue Wang1,2, Dixian Luo3,5 and Dan Xiong1,3*  \nAbstract  \nBackground Cervical cancer remains a significant global health burden, and effective triage strategies are urgently needed for high-risk human papillomavirus (hrHPV)-positive women in screening programs. This study aimed to identify and validate DNA methylation markers for detecting cervical precancerous lesions in hrHPV-positive women. Methods Reduced representation bisulfite sequencing (RRBS) was performed on a discovery cohort (n = 17) to screen for differentially methylated candidate genes. Quantitative methylation-specific PCR (qMSP) was used to evaluate the performance of selected markers in an independent cohort of 347 hrHPV-positive women stratified into training (n = 154) and validation (n = 193) sets. Diagnostic accuracy was assessed using receiver operating characteristic (ROC) curves, sensitivity, specificity, and area under the curve (AUC) .  \nResults Among the candidates identified, CNTNAP2 and PAX1 methylation levels increased progressively with cervical disease severity (both P \u003C 0. 0001) . In the independent validation set, the combined CNTNAP2/PAX1 panel achieved an AUC of 0.904 (95% CI: 0 .853–0. 942) for CIN2 +detection and 0.932 (95% CI: 0 .887–0. 963) for CIN3 +detection. The panel yielded a sensitivity of 73.8% and specificity of 95.5% for CIN2+, and a sensitivity of 89.2% and specificity of 87. 8% for CIN3+ . In comparison, HPV16/18 genotyping showed sensitivities of 54 . 1% for CIN2 +and 56. 8% for CIN3+, with specificities of 81 . 1% and 76 . 3%, respectively. Cytology (≥ ASCUS) had higher sensitivity (CIN2+: 93 . 1%; CIN3+: 91. 2%) but substantially lower specificity (CIN2+: 16. 9%; CIN3+: 14. 9%); notably, cytology specificity in this cohort was likely underestimated due to verification bias. The CNTNAP2/PAX1 panel outperformed both comparator methods in overall diagnostic accuracy.  \n*Correspondence: Dan Xiong [sunny543@126.com](sunny543@126.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nHe et al. BMC Cancer (2026) 26:847 Page 2 of 12  \nConclusions The CNTNAP2/PAX1 methylation panel demonstrates robust diagnostic performance for detecting cervical precancerous lesions in hrHPV-positive women, supporting its potential utility as an objective and effective triage tool in hrHPV-based cervical cancer screening.  \nKeywords CNTNAP2, PAX1, DNA methylation, Reduced representation bisul","cbCaio6Yz3DlaKV4","https://ap.wps.com/l/cbCaio6Yz3DlaKV4","pdf",3156567,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n## Global burden and screening needs\n## Role and limitations of HPV testing and cytology\n## Rationale for DNA methylation testing","[{\"question\":\"What was the main goal of the study?\",\"answer\":\"To identify and validate DNA methylation markers, specifically CNTNAP2 and PAX1, for detecting cervical precancerous lesions in hrHPV-positive women.\"},{\"question\":\"How were the methylation markers discovered and tested?\",\"answer\":\"Reduced representation bisulfite sequencing was used on a discovery cohort to screen candidate genes, and quantitative methylation-specific PCR evaluated performance in an independent training/validation cohort.\"},{\"question\":\"How did the CNTNAP2/PAX1 panel perform in detecting CIN2+ and CIN3+?\",\"answer\":\"In the independent validation set, the combined panel achieved AUC values of 0.904 for CIN2+ and 0.932 for CIN3+, with high specificity for both endpoints and sensitivity reported for each disease level.\"},{\"question\":\"How did the panel compare with existing triage methods?\",\"answer\":\"The CNTNAP2/PAX1 panel outperformed HPV16/18 genotyping and showed better overall diagnostic accuracy than cytology, which had higher sensitivity but substantially lower specificity and possible underestimation due to verification bias.\"}]","Identification and validation of CNTNAP2/PAX1 hypermethylation as an epigenetic biomarker panel for detection of cervical cancer and precancerous lesions in hrHPVpositive women | PDF",1790096746,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c5b8622b8c39453a9fc51a87cca43cf.webp",983,1310,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bde4c43b379688088df2cb3c87e56209.webp",982,1309,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a3ecbef394c990e8aa2bf1fbaec02db.webp",981,1308,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89710390103fd9876bf39bcb3afa2ae3.webp",980,1306]